Virax Biolabs Group Limited (VRAX)
(Delayed Data from NSDQ)
$1.94 USD
+0.01 (0.52%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $1.95 +0.01 (0.52%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VRAX 1.94 +0.01(0.52%)
Will VRAX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VRAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRAX
Zacks Investment Ideas feature highlights: Virax Biolabs Group, GeoVax Labs, Applied DNA Sciences and Emergent BioSolutions
WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch
VRAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for VRAX
Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.
Cosmos Health secures exclusivity agreement with Virax Biolabs
Virax Biolabs extends distribution agreement to market Mpox detection kits
Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In August 2024 – Where Do Tesla, Nvidia, Apple, AMD Stock Rank?